

## Supplementary Online Content

Linz MO, Bressler NM, Chaikitmongkol V, et al. Vision preference value scale and patient preferences in choosing therapy for symptomatic vitreomacular interface abnormality. *JAMA Ophthalmol*. Published online May 10, 2018.  
doi:10.1001/jamaophthalmol.2018.1272

**eTable 1.** Questionnaire used to determine vision preference value and treatment preferences

**eTable 2.** Visual function scores of individuals with vitreomacular interface abnormality (VIA)

**eTable 3.** Mean visual function scores by type of vitreomacular interface abnormality (VIA) and clinical site

**eTable 4.** Enthusiasm for treatment for each type of vitreomacular interface abnormality (VIA) in each clinical site

**eReferences.**

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** Questionnaire used to determine vision preference value and treatment preferences

<b>Preference Value Questions</b>
<ol style="list-style-type: none"><li>1. Think of a scale from 0 to 100, where 0 is complete blindness in both eyes and 100 is perfect vision in both eyes. What number between 0 and 100 would you pick to describe how you feel about your vision in both eyes?</li><li>2. Think of a new scale from 0 to 100, where 0 is death and 100 is perfect health with perfect vision. Now imagine what it would be like if you were completely blind in both eyes but otherwise had your current health. What number between 0 and 100 would you pick to describe how you would feel about your current health if you were completely blind in both eyes? Remember, 0 is death and 100 is perfect health with perfect vision.</li><li>3. Think of the same scale from 0 to 100, where 0 is death and 100 is perfect health with perfect vision. Now imagine what it would be like if you had perfect vision in both eyes but otherwise had your current health. What number between 0 and 100 would you pick to describe how you would feel about your current health if you had perfect vision in both eyes? Remember, 0 is death and 100 is perfect health with perfect vision.</li></ol>
<b>Enthusiasm for Treatment Questions for Patients With Vitreomacular Interface Abnormality</b>
<p>When a patient has an abnormality of the retina like the abnormality that your retina doctor diagnosed, if you do not do any treatment and let nature takes its course, there is about a one in 6 chance that vision will improve by itself and a one in 17 chance that vision would worsen after 6 months.<sup>1</sup></p> <p>Now, imagine we have a surgical treatment that an eye surgeon will use a small instrument to remove the abnormality at the back part of your eye. This procedure will take place in an operating room and takes approximately 40 to 60 minutes to be completed. The discomfort of the procedure would be similar to having cataract surgery which you will have an anesthetic to numb the nerves in and around your eyes before the surgery. After the surgery, it is common that your eye may be sensitive to light and touch or has mild discomfort for one or two days. Your doctors may ask you to use eye drops to help healing and decrease the risk of infection for a few days after surgery. Problems after the surgery are rare, but they can occur. These problems can include infection, bleeding, inflammation (pain, redness, and swelling), loss of vision, tear or detachment of the retina, development of cataract requiring cataract surgery, need for injection of air bubble lasting several days into the middle cavity of the eye to reduce risk of retinal detachment, and high or low eye pressure.</p> <p>If you were offered a surgical treatment when you were first diagnosed that had a one in 5 chance of improving the vision in your affected eye but there was a one in 5 chance your vision might decrease<sup>2</sup>, what would your enthusiasm be for this procedure? Would you be “not enthusiastic,” “slightly enthusiastic,” “moderately enthusiastic,” or “very enthusiastic”?</p> <p>Now, imagine we have a medicine designed to improve the vision in your eye that we inject with a small needle into the middle of your eye. This procedure will take place in a clinic room and take approximately 5 to 10 minutes to be completed. The discomfort of the procedure would be similar to pressing on your eye with a cotton swab. Problems after the injection are rare, but they can occur. These problems can include infection, bleeding, cataract, retinal detachment, and loss of vision. If the injectable medicine, with or without vitrectomy, had a one in 4 chance of improving vision in your affected eye but there was a one in 13 chance your vision might decrease<sup>1</sup>, what would your enthusiasm be for this procedure? Would you be “not enthusiastic,” “slightly enthusiastic,” “moderately enthusiastic,” or “very enthusiastic”?</p>

<sup>a</sup> Based on questionnaire previously validated by The Submacular Surgery Trials.<sup>3</sup>

**eTable 2.** Visual function scores<sup>a</sup> of individuals with vitreomacular interface abnormality (VIA)

<b>Category</b>	<b>Mean ± Standard Deviation<sup>b</sup> (n=209)<sup>c</sup></b>	<b>Median<sup>b</sup> (n=209)<sup>c</sup></b>
General vision	65.55 ± 13.86	60.00
Ocular pain	87.44 ± 18.08	100.00
Near activities	76.52 ± 19.85	83.33
Distance activities	78.79 ± 20.65	83.33
Social functioning	87.26 ± 19.34	100.00
Mental health	72.67 ± 20.06	81.25
Role difficulties	74.64 ± 26.66	75.00
Dependency	91.99 ± 17.88	100.00
Driving	70.83 ± 27.80	75.00
Color vision	95.81 ± 13.33	100.00
Peripheral vision	85.29 ± 19.51	100.00
Composite score	80.69 ± 14.07	84.13

<sup>a</sup>Visual function scores were determined using the National Eye Institute Visual Functioning Questionnaire-25.<sup>4</sup>

<sup>b</sup>Maximum value for any category is 100. <sup>c</sup>Four participants who deferred questions related to preference value were excluded.

**eTable 3.** Mean visual function scores<sup>a</sup> by type of vitreomacular interface abnormality (VIA) and clinical site<sup>b</sup>

Subscale Category <sup>c</sup>	Vitreomacular Traction			Epiretinal Membrane			Macular Hole		
	Thailand (n=5)	UK (n=3)	US (n=5)	Thailand (n=52)	UK(n=14)	US (n=32)	Thailand (n=43)	UK (n=39)	US (n=16)
General vision	64.0	66.7	64.0	61.5	60.0	72.5	63.7	63.6	80.0
Ocular pain	77.5	100.0	97.5	81.5	88.4	94.5	87.5	85.3	94.5
Near activities	85.0	88.9	66.7	78.0	80.4	78.4	76.1	68.8	82.8
Distance activities	85.8	100.0	80.8	75.4	86.3	79.2	75.6	79.4	82.8
Social functioning	90.0	95.8	97.5	80.8	91.1	94.1	79.9	89.7	99.2
Mental health	81.3	83.3	70.0	76.8	66.1	75.2	75.1	60.1	80.1
Role difficulties	80.0	87.5	85.0	72.6	72.3	80.1	73.3	67.3	86.7
Dependency	93.3	91.7	83.3	95.2	92.3	90.4	97.5	80.8	99.5
Driving	79.2	95.8	81.7	64.0	76.7	76.6	67.2	60.6	87.5
Color vision	95.0	91.7	100.0	96.2	100.0	95.3	93.6	95.5	98.4
Peripheral vision	85.0	100.0	100.0	82.7	85.7	89.8	80.2	82.7	96.9
Composite score	83.4	90.5	84.2	79.1	81.7	84.2	79.3	75.7	89.9

<sup>a</sup>Visual function scores were determined using the National Eye Institute Visual Functioning Questionnaire-25.<sup>4</sup>

<sup>b</sup>Four participants who deferred questions related to preference value were excluded.

<sup>c</sup>Maximum value for any category is 100.

**eTable 4.** Enthusiasm for treatment for each type of vitreomacular interface abnormality (VIA) in each clinical site

Diagnosis	Treatment	Enthusiasm	Clinical Site (n=209) <sup>a</sup>			Total Patients at Each Enthusiasm Level
			Thailand n(%)	United Kingdom n(%)	United States n(%)	
Vitreomacular traction (n=13)	Vitreotomy	Not enthusiastic	1 (7.7%)	0 (0.0%)	1 (7.7%)	2
		Slightly enthusiastic	0 (0.0%)	0 (0.0%)	2 (15.4%)	2
		Moderately enthusiastic	1 (7.7%)	1 (7.7%)	2 (15.4%)	4
		Very enthusiastic	3 (23.1%)	2 (15.4%)	0 (0.0%)	5
	Injection	Not enthusiastic	1 (7.7%)	1 (7.7%)	2 (15.4%)	4
		Slightly enthusiastic	1 (7.7%)	0 (0.0%)	1 (7.7%)	2
		Moderately enthusiastic	1 (7.7%)	1 (7.7%)	1 (7.7%)	3
		Very enthusiastic	2 (15.4%)	1 (7.7%)	1 (7.7%)	4
Epiretinal membrane (n=98)	Vitreotomy	Not enthusiastic	4 (4.1%)	2 (2.0%)	13 (13.3%)	19
		Slightly enthusiastic	2 (2.0%)	5 (5.1%)	3 (3.1%)	10
		Moderately enthusiastic	15 (15.3%)	6 (6.1%)	14 (14.3%)	35
		Very enthusiastic	31 (31.6%)	1 (1.0%)	2 (2.0%)	34
	Injection	Not enthusiastic	11 (11.2%)	5 (5.1%)	10 (10.2%)	26
		Slightly enthusiastic	7 (7.1%)	1 (1.0%)	7 (7.1%)	15
		Moderately enthusiastic	20 (20.4%)	4 (4.1%)	14 (14.3%)	38
		Very enthusiastic	14 (14.3%)	4 (4.1%)	1 (1.0%)	19
Macular hole (n=98)	Vitreotomy	Not enthusiastic	3 (3.1%)	5 (5.1%)	3 (3.1%)	11
		Slightly enthusiastic	4 (4.1%)	8 (8.2%)	4 (4.1%)	16
		Moderately enthusiastic	12 (12.2%)	18 (18.4%)	6 (6.1%)	36
		Very enthusiastic	24 (24.5%)	8 (8.2%)	3 (3.1%)	35
	Injection	Not enthusiastic	8 (8.2%)	13 (13.3%)	5 (5.1%)	26
		Slightly enthusiastic	11 (11.2%)	3 (3.1%)	3 (3.1%)	17
		Moderately enthusiastic	15 (15.3%)	11 (11.2%)	5 (5.1%)	31
		Very enthusiastic	9 (9.2%)	12 (12.2%)	3 (3.1%)	24

<sup>a</sup>Four participants who deferred questions related to preference value were excluded.

## eReferences.

1. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Transplant and Ophthalmology Products, Dermatologic and Ophthalmic Drugs Advisory Committee Meeting Briefing Package for Ocriplasmin Intravitreal Injection, 2.5 mg/mL; Proposed Indication: Treatment of symptomatic vitreomacular adhesion including macular hole. July 26, 2012.
2. Freeman WR, Azen SP, Kim JW, et al. Vitrectomy for the treatment of full-thickness stage 3 or 4 macular holes: Results of a multicentered randomized clinical trial. *Arch Ophthalmol*. 1997;115:11-21.
3. Bass EB, Marsh MJ, Mangione CMS, et al. Patients' perceptions of the value of current vision: Assessment of preference values among patients with subfoveal choroidal neovascularization—The submacular surgery trials vision preference value scale: SST report no. 6. *Arch Ophthalmol*. 2004;122(12):1856-1867.
4. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25). *Arch Ophthalmol*. 2001;119(7):1050-1058.